Navigation Links
Chemoembolization Improving as Liver Cancer Treatment
Date:1/19/2009

these microspheres absorb the chemotherapeutic agent, and then the drug is released directly into the tumor.

A month after treatment, tumors in 27 of the patients (51 percent) showed a complete response, 18 (34 percent) showed a partial response and eight (15 percent) showed stable disease. Six months later 19 of 34 patients (55.9 percent) had complete tumor response, eight (23.5 percent) had a partial response and seven (20.5 percent) had growing disease. Of the remaining 19 patients, three died, four were lost at follow-up and 12 receive other treatments.

"Patients who still had good liver function and who had tumors in only one lobe of the liver did better with this treatment," said Maurizio Grosso, M.D., chairman of the Department of Radiology at Santa Croce & Carle Hospital, Cuneo, Italy. "We're hopeful that treatment with HepaSphere will be an improvement over traditional chemoembolization."

Embolization without Chemotherapy

Researchers at the European Institute of Oncology in Milan, Italy, are studying using embolization without the chemotherapy for liver cancer. The study included 25 patients with 34 primary liver tumors. All patients received Embozene(TM) microspheres alone, without the addition of any chemotherapeutic agents in the beads. The patients had 35 sessions with the microspheres. After one month follow-up, 18 tumors (52 percent) had shrunk in size while 16 (48 percent) were the same size with no tumor growth detected. In a group of 16 tumors with a follow up ranging between six and 12 months, two tumors (12 percent) completely disappeared, seven tumors (44 percent) continued to shrink, two (12 percent) were stable and five (31 percent) grew, although they were still of a size suitable for new local treatments. To date, 14 patients have had more than one year of follow-up care and 93 percent of them are still alive.

"One concern with embolization is th
'/>"/>

SOURCE International Symposium on Endovascular Therapy
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Stroke Study Reveals a Key Target For Improving Treatment
2. Abbotts Phase III Studies of Investigational TriLipix(TM) (ABT-335), in Combination With Statins, Meets Primary Endpoints on Improving LDL, Triglycerides and HDL
3. Reproductive Partners Participates in New IVF Progesterone Delivery System Study
4. Jennerex Treats First Patients in Phase 2 JX-594 Trial for Liver Cancer
5. Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function
6. ELAD(R) Liver Support System Study Initiated at Multiple U.S. Centers
7. Tibotec Presents Interim Findings for TMC435, an Investigational Genotype 1 Hepatitis C Treatment, at the AASLD Liver Meeting 2008
8. GSK Believes There Is No Liver Safety Issue With AVANDIA; Responds to Public Citizen Petition
9. Jennerex Completes the Treatment of First Patient Cohort in Phase 1 Trial With Intravenous Delivery of JX-594 Oncolytic Virus
10. Experts Assert That Varian Technologies Deliver Speed and Clinical Accuracy in Treating Cancer Patients
11. CEL-SCI Expects to Take Delivery of New Manufacturing Facility on October 8, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... Eisai Inc. announced today that regulatory applications ... , European Union and Japan ... eribulin, for the treatment of patients with inoperable soft ... advanced or metastatic disease. These regulatory ... Phase 3 clinical trial (Study 309), which met its ...
(Date:7/30/2015)... , July 30, 2015 ... new research report with market overview, trends, ... forecast, porter analysis, recent developments, competitive scenario ... Global Industry Insight: Biosensors Market Development and ... (Logo: http://photos.prnewswire.com/prnh/20150727/756778 ) Explore ...
(Date:7/30/2015)... July 30, 2015   Gaumard® Scientific Company ... UNI®, the world,s first operating system to support ... available exclusively to Gaumard users. UNI® version 2.27.21.0 ... Newborn Tory™ S2200, as well as improvements to ... clinical measures such as EtCO 2 .  ...
Breaking Medicine Technology:Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 2Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 3Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 4Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 5Gaumard's Latest UNI Operating System Update Adds Performance and New Functionality 2Gaumard's Latest UNI Operating System Update Adds Performance and New Functionality 3
(Date:7/31/2015)... ... July 31, 2015 , ... Nutritional ... variety of nutritional and wellness products, announced the addition of Vincent Aquilino to ... therapy, active isolated stretching and the prevention and rehabilitation of injuries, has spent ...
(Date:7/31/2015)... ... July 31, 2015 , ... Intellitec Solutions ... recent implementation of Microsoft Dynamics GP for a senior living facility in Maine. ... supporting senior living communities in 16 states. This further expansion was again a ...
(Date:7/31/2015)... ... July 31, 2015 , ... ... the growing number of individuals who remain undiagnosed, treatment options for patients are ... away from traditional CPAP therapy due to its overall lack of comfort and ...
(Date:7/30/2015)... ... 31, 2015 , ... Reduce Human Error on the Drug ... and Ginette M. Collazo, Inc.**, Sept. 16-17, 2015 – Raleigh, NC, http://www.fdanews.com/humanerrordrugdevice ... and device firms reduce manufacturing errors by 50 percent or more, will conduct ...
(Date:7/30/2015)... New York (PRWEB) , ... July 31, 2015 , ... ... Obama’s call to action by asking community members to contribute to the College’s “My ... “Helping more of our young people stay on track. Providing the support they need ...
Breaking Medicine News(10 mins):Health News:NPI Welcomes Vincent Aquilino to Board of Directors 2Health News:Intellitec Solutions Expands Long term Care ERP Offerings to Maine 2Health News:Oravan Sleep Apnea Device Gains Traction in Sleep Industry 2Health News:FDAnews Announces — Reduce Human Error on the Drug and Device Manufacturing Floor: Reduce Errors By 50% or More Workshop, Sept. 16-17, 2015 2Health News:FDAnews Announces — Reduce Human Error on the Drug and Device Manufacturing Floor: Reduce Errors By 50% or More Workshop, Sept. 16-17, 2015 3Health News:FDAnews Announces — Reduce Human Error on the Drug and Device Manufacturing Floor: Reduce Errors By 50% or More Workshop, Sept. 16-17, 2015 4Health News:Mercy College a “My Brother’s Keeper” Community 2Health News:Mercy College a “My Brother’s Keeper” Community 3
... transmission did not cause infection among caregivers in study ... study estimates that more than 12 percent of people ... infected with MRSA, or methicillin-resistant Staphylococcus aureus, and ... to others in their household. , The researchers, Dr. ...
... the cheerful, study finds , MONDAY, Aug. 10 (HealthDay News) ... more likely to develop heart trouble than those with a ... comes from the Women,s Health Initiative, which has tracked more ... , "In addition to looking at hormones and their effect ...
... , , WASHINGTON, Aug. 10 ... is an immigrant (legal or illegal) or the U.S.-born child (under ... one-fourth of those on Medicaid. While there has been some ... insurance plans, the enormous impact of immigration, both legal and illegal, ...
... , ROLLING HILLS ESTATES, Calif., ... Device Connectivity Conference & Exhibition, organized by The Center for ... at the Joseph B. Martin Conference Center at Harvard Medical ... an outstanding agenda with nationally recognized experts from academia, provider ...
... , , FLORENCE, Italy, Aug. 10 ... a North American subsidiary of its DEKA division. Based in San ... bringing a selected range of medical and aesthetic devices under the ... SmartXide DOT. , , The new management team ...
... , LAKEWOOD, N.J., Aug. 10 PLUS ... announced today that it has expanded its executive team with the addition ... M.D. to chief medical officer and Mark Machulcz to executive vice president ... Mr. Machulcz bring more than 30 years of combined anatomic pathology experience ...
Cached Medicine News:Health News:Staph Infection May Follow People Home From Hospital 2Health News:Optimism Good for Heart and Longevity 2Health News:Optimism Good for Heart and Longevity 3Health News:Inaugural Medical Device Connectivity Conference & Exhibition to Focus on Connecting Medical Devices to People, Workflow and Information Systems 2Health News:El.En. Group Establishes New Subsidiary, DEKA Medical, Inc. and Appoints Management Team 2Health News:PLUS Diagnostics Announces Senior Executive Appointments 2Health News:PLUS Diagnostics Announces Senior Executive Appointments 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: